No Data
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Arvinas, Inc.'s (NASDAQ:ARVN) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
BofA Securities Maintains Arvinas(ARVN.US) With Buy Rating, Raises Target Price to $57
Analysts' Opinions Are Mixed on These Healthcare Stocks: Outset Medical (OM), Arvinas Holding Company (ARVN) and Innovent Biologics (OtherIVBXF)
Buy Rating for Arvinas Holding Company Driven by Vepdeg's Promising Potential and Market Opportunity
Barclays Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $48
Revenues Not Telling The Story For Arvinas, Inc. (NASDAQ:ARVN) After Shares Rise 28%
